According to the WHO definition, probiotics are 'live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.' These are orally delivered, carefully selected bacterial or yeast cultures.

Not all lactic acid bacteria from the Lactobacillus or Bifidobacterium genera have a scientifically documented impact on human health.

The probiotic properties are not associated with the bacterial species but rather with the strain type; probiotic properties are strain-dependent.

A proper description of a probiotic strain should include three components in the systematic name, specifying: genus, species, and strain, e.g., Lactobacillus (genus) rhamnosus (species) GG (strain). In reality, each strain requires separate research to determine its probiotic properties and effectiveness.

Research results for one strain cannot be used as evidence of the effectiveness of another strain, even if they are closely related.

 

LACTOSPORE®

Clinically Tested and Safe Probiotic

LactoSpore®:

• Discovered in 1933 originally under the name Latobacillus sporogenes – currently known as Bacillus coagulans,
• Gram-positive bacteria,
• Naturally microencapsulated for stability,
• Produces only L+ lactic acid, the biologically active form,
• Replicates in the gastrointestinal tract,
• Optimal growth temperature is 30°C to 37°C, with an optimal pH range of 5.5 to 6.2,
• Due to its spore-forming nature, LactoSpore® survives production, shipping, and storage without loss of viability,
• Does not require refrigeration conditions,
• Confirmed to be stable at room temperature through research.

The acidic environment created by the production of L (+) lactic acid and other antimicrobial compounds prevents the development of microbe-induced diseases, such as Clostridia, which are responsible for the production of undesirable gases.

LactoSpore produces bacteriocins (antimicrobial protein compounds) that inhibit both Gram-positive and Gram-negative bacteria.

 

EFFECTIVENESS CONFIRMED BY RESEARCH

A clinical study conducted on 567 individuals in 19 institutions in Japan.

Condition | % Improvement

Diarrhea due to acute or chronic inflammation of the stomach and intestines | 93.7%

Indigestion with accompanying diarrhea | 85.9%

Infantile diarrhea | 87.9%

Constipation | 65.4%

ANTI-DIARRHEAL EFFECTIVENESS COMPARABLE TO THE EFFECTIVENESS OF LOPERAMIDE, ATROPINE SULFATE.

IRRITABLE BOWEL SYNDROME IBS

Abdominal Pain – Improvement | Gastrointestinal Discomfort

Improved Quality of Life

High dose of Bacillus Coagulans MTCC 5856 bacteria demonstrated effectiveness in combating Irritable Bowel Syndrome and other indications, as confirmed by research.

2x 10 billion daily for 90 days

Effectiveness in Vaginal Inflammation

Complete relief in 91% of patients

Partial relief in 9% of patients

Safety of Use

A double-blind, randomized, placebo-controlled trial in humans to assess the safety of Bacillus Coagulans MTCC 5856 usage.

Dose: 2 billion daily for 30 days

B. Coagulans MTCC 5856 is safe and well-tolerated

STABILITY AND SURVIVABILITY

• Stable and enduring at room temperature,
• Effectiveness confirmed in multiple indications (IBS, constipation, diarrhea),
• Quick action in as little as 1.8 days,
• Free from milk, GMO, nanotechnology, KOSHER, HALAL,
• Suitable for vegans and vegetarians - vegan capsule,
• Dosage: 1-2 capsules per day.